biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
Company profile
Ticker
BIOCQ
Exchange
Website
CEO
Michael Nall
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
BIOCQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
20 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Oct 23
8-K
Bankruptcy or Receivership
16 Oct 23
8-K
Biocept Reports Second Quarter 2023 Financial Results
22 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Departure of Directors or Certain Officers
21 Jun 23
424B4
Prospectus supplement with pricing info
25 May 23
EFFECT
Notice of effectiveness
25 May 23
S-1/A
IPO registration (amended)
23 May 23
CORRESP
Correspondence with SEC
23 May 23
Transcripts
BIOCQ
Earnings call transcript
2022 Q3
28 Nov 22
BIOCQ
Earnings call transcript
2021 Q3
16 Nov 21
BIOCQ
Earnings call transcript
2021 Q2
17 Aug 21
BIOCQ
Earnings call transcript
2021 Q1
12 May 21
BIOCQ
Earnings call transcript
2020 Q4
30 Mar 21
BIOCQ
Earnings call transcript
2020 Q3
13 Nov 20
BIOCQ
Earnings call transcript
2020 Q2
12 Aug 20
BIOCQ
Earnings call transcript
2020 Q1
13 May 20
BIOCQ
Earnings call transcript
2019 Q4
25 Mar 20
BIOCQ
Earnings call transcript
2019 Q3
13 Nov 19
Latest ownership filings
3
Robert Walsh
20 Jun 23
SC 13G
Lind Global Fund II LP
2 Jun 23
4
QUYEN THI DAO-HADDOCK
18 Nov 22
3
QUYEN THI DAO-HADDOCK
18 Nov 22
4
Marsha Alpert Chandler
8 Sep 22
4
Linda M Rubinstein
8 Sep 22
4
Bruce Gerhardt
8 Sep 22
4
IVOR ROYSTON
8 Sep 22
4
Margaret Faye Wilson
8 Sep 22
4
Darrell Taylor
4 Apr 22
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
46.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 4 |
Closed positions | 19 |
Increased positions | 0 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 112.57 mm |
Total shares | 1.23 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 607.28 k | $2.73 mm |
Lincoln Park Capital Fund | 394.26 k | $13.17 mm |
Lind Global Fund II | 147.29 k | $318.00 k |
Anson Funds Management | 44.86 k | $54.28 mm |
Boothbay Fund Management | 23.53 k | $28.47 mm |
Tower Research Capital | 5.39 k | $6.52 mm |
BLK Blackrock | 5.26 k | $6.37 mm |
Group One Trading | 270.00 | $327.00 k |
JPM JPMorgan Chase & Co. | 268.00 | $324.00 k |
Acadian Asset Management | 247.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Nov 22 | Quyen Thi Dao-haddock | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.81 | 10,000 | 8.10 k | 10,000 |